211 results
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
patients with cancers
I/C
F-NLR scoring system, high F-NLR score vs. low F-NLR score
O
overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS)
P
health professionals (HPs)
I/C
formal R/S-training, physicians, nurses
O
belief in influence of R/S on patients' health, prevalence of formal R/S-training
P
bladder cancer (BC) patients
I/C
18 F-FDG PET/CT, clinical response and nonresponse
O
tumor response to neoadjuvant chemotherapy
P
metastatic or recurrent gastric cancer patients
I/C
capecitabine-based chemotherapy, S-1-based chemotherapy
O
objective response rate, 6-, 12-, and 18-month progression-free survival, 1-, 2-, and 3-year overall survival, adverse events (hand-foot syndrome, neutropenia)
P
thyroid cancer (TCa) patients
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT), ultrasonography (US)
O
detection of cervical lymph node (LN) metastasis
P
patients with vertebral compression fractures
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), differentiation of benign and malignant vertebral compression fractures
O
diagnostic performance, sensitivity, specificity, positive likelihood ratio, negative likelihood ratio
P
GSNO
I/C
S-Nitrosoglutathione, Placebo
O
Infarct size, Neurological behavior scales, Embolic signals
P
PD patients
I/C
5-HTTLPR genotype (S/S-Allele), PD patients without depression
O
Depression risk
P
COVID-19 survivors (S), nonsurvivors (NS)
I/C
echocardiographic systolic pulmonary arterial pressure (sPAP) measurement, sPAP difference between nonsurvivors and survivors
O
11.8mmHg (95% CI, 6.60-16.97; P < 0.0001, I2 = 89.3%) higher in NS compared with S